

CURRICULUM VITAE

Natasha Kyprianou, Ph.D.

I. Personal Information:

Address: Department of Surgery, Division of Urology
University of Kentucky College of Medicine
800 Rose Street, 306 Combs Building
Lexington, KY 40536-0096

Phone: (859) 323-9812
Fax: (859) 323-1944
Email: nkypr2@uky.edu

II. Education:

1977 – 1978 Advanced Level G.C.E. in Chemistry, Physics and Pure Mathematics; London University, London, UK

1978 – 1981 B.Sc. (Honors) in Biochemistry, Queen Mary College, University of London, London, UK

1981 – 1983 M.B., University of Leeds, Leeds, UK

1983 – 1986 Ph.D. in Molecular Endocrinology, University of Wales College of Medicine, Cardiff, S. Wales, UK

III. Academic Training/Professional Education:

1987 – 1990 Urologic Oncology Fellowship, Department of Urology and the Oncology Center, Johns Hopkins University School of Medicine, Baltimore

1990 – 1991 Senior Research Fellow, Imperial Cancer Research Fund, London, UK

IV. Present Positions:

2002 – present **James F. Hardymon Chair in Urologic Research**
University of Kentucky Medical Center
Lexington, Kentucky

2002 – present **Professor of Urology, Division of Urology, Department of Surgery and the Markey Cancer Center**
University of Kentucky Medical Center
Lexington, Kentucky

- 2002 – present** **Professor of Molecular and Cellular Biochemistry, Department of Molecular Biochemistry**
University of Kentucky Medical Center
Lexington, Kentucky
- 2003 – present** **Professor, Department of Pathology and Laboratory Medicine**
University of Kentucky Medical Center
Lexington, Kentucky
- 2004 – present** **Professor, Graduate Center for Toxicology**
University of Kentucky Graduate School
Lexington, Kentucky

V. Previous Positions:

- 1992 – 1998** **Assistant Professor of Urology, Department of Surgery, Division of Urology**
University of Maryland School of Medicine
Baltimore, Maryland
- 1992 – 1998** **Assistant Professor of Biochemistry and Molecular Biology, Department of Biochemistry and Molecular Biology**
University of Maryland School of Medicine
Baltimore, Maryland
- 1992 – 2002** **Director, Urological Research, Division of Urology**
University of Maryland School of Medicine
Baltimore, Maryland
- 1998 – 2002** **Associate Professor (with tenure) of Urology and Oncology, Department of Surgery, and Greenbaum Cancer Center**
University of Maryland School of Medicine
Baltimore, Maryland
- 1998 – 2002** **Associate Professor of Biochemistry and Molecular Biology, Department of Biochemistry and Molecular Biology**
University of Maryland School of Medicine
Baltimore, Maryland

VI. Research Experience:

- 2002 – 2006** **Associate Director of Research, Department of Surgery**
University of Kentucky Medical Center
Lexington, Kentucky

- 2004- present** **Member Graduate Faculty**, Molecular and Cellular Biochemistry Program, University of Kentucky, Lexington, Kentucky
- 1992 – 2001** **Director, Resident Research Program, Division of Urology**
University of Maryland Medical System
Baltimore, Maryland
- 1993 – 1996** **Research Mentor to General Surgery Residents, Department of Surgery** University of Maryland Medical System
Baltimore, Maryland

VII. Awards and Honors:

- 1983** Doctoral Scholarship, Tenovus Cancer Research Foundation, S. Wales
- 1990** Imperial Cancer Research Fund Fellowship, London, UK
- 1993** A.F.U.D./A.U.A New Investigator Research Award
- 1996** A.U.A/CapCURE Contest Winner, AUA Meeting, Orlando, Florida
- 1996** CapCURE Research Award
- 1997** Society for Basic Urologic Research Young Investigator Award
- 1997** Urological Sciences Research Foundation Award for Research Excellence
- 2002** James F. Hardymon Distinguished Chair in Urology Research
- 2003** Honorary Kentucky Colonel, Commonwealth of Kentucky
- 2004** Honorary Member, Board of Directors European Society for Urologic Research
- 2005** Abraham Flexner Master Educator Award for Outstanding Teaching/Mentorship, Center for Excellence in Medical Education, University of Kentucky
- 2006** Society for Women in Urology/AUA/SBUR Inaugural Award for Outstanding Contributions to Urology Research
- 2008** American Urological Association Foundation Distinguished Mentor Award

VIII. Professional Memberships:

- 1990 – 1992** British Association for Cancer Research
- 1991 –** Society for Basic Urologic Research
- 1992 –** American Association for Cancer Research
- 1994 –** New York Academy of Sciences
- 1994 –** American Association for the Advancement of Science
- 1995 –** American Urological Association
- 1995 –** European Society for Urologic Research
- 1996 –** Society of Women in Urology
- 2003 –** American Society of Andrology
- 2006 –** International Cell Death Society
- 2007 –** British Pharmacological Society

IX. Committees:

- 1993 – 2001** Member, Center for Studies in Reproduction, University of Maryland.
- 1994 – 2001** Member, University of Maryland Graduate School Program
- 1994 – 1996** Member, Membership Committee, Society for Basic Urological Research
- 1994 – 1998** Member, Bressler-Pangborn Awards Committee, University of Maryland School of Medicine Intramural Grants
- 1995 – 1997** Member, University of Maryland Cancer Center Research Committee
- 1995 – 1998** Member, Urological Malignancies Task Force, University of Maryland
- 1997 – 1998** Member, Executive Membership Committee, American Association for Cancer Research
- 1997 – 1999** Member, Awards Committee, Society for Basic Urologic Research
- 1997 – 2001** Member, American Cancer Society Advisory Board, Committee on Molecular Genetics and Oncogenes
- 1999 – 2000** Member, NIH Operations SBUR subcommittee
- 2000** Ph.D. Thesis Committee Member: Dmitry Grigorev, Thesis Title: “Aromatase Inhibitors for the Treatment of Prostate Cancer”
Thesis Advisor: Dr. Angela Brodie, Professor Department of Pharmacology, University of Maryland School of Medicine, Baltimore
- 2001** Ph.D. Thesis Committee Member: Karla Sommerville-Amstrong, Thesis Title: “Novel Affinity Reagents for Cross-Linking Human Hemoglobin”;
Thesis Advisor: Dr. Ram Hosmane, Professor, Department of Chemistry, University of Maryland Baltimore County, Baltimore
- 2002 –** Interviewer, Medical School Admission, University of Kentucky
- 2003 –** Ph.D. Thesis Committee Member: Robert Joseph McCorkle, Thesis title: “NM23 in Cancer Cell Metastasis”;
Thesis Advisor: Dr. David Kaetzel, Professor, Department of Molecular Pharmacology, University of Kentucky, Lexington
- 2004 – 2006** Ph.D. Thesis Committee Member: Maria Theodosiou; Thesis title: “Role of the Transcription Coregulator NPDC-1 in Retinoid and Thyroid Receptor Signaling in the Axolotl *Ambystoma Mexicanum*”; Thesis Advisor: Dr. Dan Noonan, Department of Molecular and Cellular Biochemistry, University of Kentucky
- 2005 – 2006** Ph.D. Thesis Committee Member: Brigham Barber; Thesis title: “Androgen Signaling and the Muscle”; Thesis Advisor: Dr. Karyn Essen, Department of Physiology, University of Kentucky
- 2006 –** Ph.D. Thesis Committee Member: Yekaterina Zaytseva; Thesis title: “PARR γ Receptor Regulation in Breast Cancer”; Thesis Advisor: Dr. Michael Kilgore, Department of Pharmacology, University of Kentucky
- 2006 –** Ph.D. Thesis Committee Member: Marian Novak; Thesis title: “Metastasis Suppressor Gene nm23 in Melanoma”; Thesis Advisor: Dr. David Kaetzel, Department of Molecular Pharmacology, University of Kentucky

- 2007 – Chair, Surgery Research Grant Review Committee, University of Kentucky
- 2007 – Ph.D. Thesis Committee Member: Perry Christian; “Antigen-Induced Cell Death and Proteasome Inhibition, A Synergistic Cancer Therapy;” Thesis Advisor: Dr. Steven Schwarze, Department of Molecular Biochemistry
- 2007 Molecular Oncology Faculty Search Committee, Markey Cancer Center, University of Kentucky
- 2007 AUA Research Scholar Review Committee, Chicago, IL
- 2008 – Ph.D. Thesis Committee Member: Michael Fiandalo; Thesis Advisor: Dr. Steven Schwarze, Department of Molecular Biochemistry
- 2009 – Molecular and Biomedical Pharmacology Review Committee, University of Kentucky

X. Other Significant Scholarly, Research or Administrative Experience:

- 2002 – present **James F. Hardymon Chair in Urologic Research**
University of Kentucky Medical Center
Lexington, Kentucky
- 2004 – 2005 **Member**, CAART Committee, Markey Cancer Center, University of Kentucky
- 2006 – 2008 **Member**, Strategic Planning Committee for Prostate Clinical/Basic Science, NIDDK/NIH
- 2006 – present **Member**, IMPaCT: “Innovative Minds in Prostate Cancer Today,”
Department of Defense, Prostate Cancer Research Program
- 2006 – present **Member**, Programmatic Committee Integration Panel, Department of Defense, Prostate Cancer Congressionally Directed Research Program

Teaching Experience:

- 1993 – 2000 Conference Leader, Medical Biochemistry Course, Medical Student Teaching Program, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine
- 1994 – 2001 Lecturer, Molecular Biology and Advanced Molecular Biology Courses, Graduate Program, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine
- 1996 – 1999 Lecturer, Biology of Cancer Course, Department of Pathology, University of Maryland School of Medicine
- 1997 – 1999 Course Director and Lecturer, FAES Workshop on “Apoptosis in Normal Homeostasis and Disease Development and Treatment” NIH, Bethesda, MD

2000 – 2002	Lecturer, Cell and Molecular Biology Course, First Year Medical Students, University of Maryland School of Medicine, Baltimore
2003 – present	Lecturer, Biochemistry Course (401), Undergraduate Students, University of Kentucky, Lexington
2003 – present	Course Instructor, Cell Biology and Signaling Course (IBS 603); University of Kentucky College of Medicine, Lexington
2004 – present	Lecturer, Cancer Biology Course, IBS Graduate Program (IBS 616), University of Kentucky College of Medicine, Lexington
2004 – present	Lecturer, Molecular Epidemiology and Cancer Prevention Class; SPH718, Markey Cancer Center, University of Kentucky, Lexington
2007	CRS Seminar presentation, “Targeting apoptotic pathways in treating prostate cancer”, University of Kentucky, November 2007.
2008	Lecturer, Mechanisms of Human Diseases, PGY 630-020, Physiology Department, University of Kentucky.
2008	Lecturer, Hematology/Oncology Grand Rounds, University of Kentucky, April 2008.

Study Section/Review Panel Activities:

1992	Member, Special Review Panel for Specialized Programs of Research Excellence (SPORE) in Prostate Cancer, National Cancer Institute (NCI), Bethesda, MD
1995 – 1999	Member, Review Committee, University of Maryland Cancer Center Research Grants
1996 – 2004	Ad Hoc Reviewer, General Medicine Study Section, Urology Special Emphasis Panel (SEP), NIH
1997 – 2002	Ad Hoc Reviewer, Oncology Merit Review Board, VA Medical Research Service.
1997 – 2004	Research Grants Review Committee Member, American Foundation for Urologic Disease
1997 – 2000	Review Committee, Medical Research Council, Clinical Research Awards, UK.
1997 – 2001	Member, Advisory Committee on Molecular Genetics and Oncogenes, American Cancer Society
1998 – 2004	Member, Peer Review Committee, Cell Biology; Department of Defense Prostate Cancer Program, U.S. Army Medical Research and Materiel Command
1998 – 2003	Member, Peer Review Committee; Department of Defense Breast Cancer Program, U.S. Army Medical Research and Materiel Command
1999	Member, Peer Review Committee, George O’Brien Centers in Urology, NIDDK
2000 – 2002	Member, Peer Review Committee (Cell Biology), California Cancer Research Program, San Francisco, CA
2000	Ad Hoc Reviewer, New Jersey Cancer Research Program

2000 Reviewer, National Cancer Institute Program Project Review/Site Visit; Memorial Sloan Kettering Cancer Center, New York

2000 Member, NIDDK-D RFA Special Grants Review Committee, Bethesda, Maryland

2001 Member, Peer Review Committee, Molecular Biology Section, Department of Defense Prostate Cancer Program, U.S. Army Medical Research and Materiel Command, Washington, D.C.

2000 – 2001 Reviewer, National Cancer Institute (NCI), Program Project on Bladder Cancer Molecular Markers, Memorial Sloan Kettering Cancer Center, Site Visit, PI: Dr. Carlos Gordon-Cardo, New York

2002 Adhoc Member, Cancer Molecular Pathobiology Study Section (CAMP), NIH

2002 Ad Hoc Reviewer, Endocrinology and Reproductive Sciences Study Section, NIH, Bethesda, Maryland

2002 Reviewer, National Cancer Institute (NCI), Program Project on Bladder Cancer, USCF Cancer Center, PI: Dr. Peter Jones

2002 – 2003 Reviewer, Cardura Competitive Research Awards, Pfizer, New York

2003 Co-Chair/Member, Peer Review Committee, George O'Brien Centers in Urology, Washington, D.C., NIH/NIDDK

2003 Adhoc Member, Parent Subcommittee D-Clinical Studies, NCI Review, NCI/NIH, Bethesda, MD

2003 Adhoc Reviewer, RFA "Molecular Targets for Nutrients in Prostate Cancer Prevention", NIH/NCI, Bethesda, MD

2003 Reviewer, Prostate Cancer Program, Irish Cancer Society

2003 – 2004 Reviewer, National Cancer Institute Site Visit, Program Project on "Apoptosis-Based Immunotherapy for Prostate Cancer"; PI: Dr. John Reed, The Burnham Institute, La Jolla, California.

2003–2008 Chartered Member, Cancer Molecular Pathobiology Study Section (CAMP), NIH, Washington, D.C.

2004 Adhoc Member, Urologic and Kidney Development & Genitourinary Diseases Study Section, Washington, D.C.

2004 Chair, Grant Review Panel, Cell Biology-4, Breast Cancer Program, U.S. Department of Defense, Arlington, VA

2004 – 2006 Member, Program Projects Cluster Review Panel; NCI Subcommittees, D and E; Washington D.C.

2004 – 2007 Chartered Member, Parent Subcommittee-C, Basic and Preclinical Review Group, National Cancer Institute, NIH, Bethesda, MD

2006-present Member/Discussion Leader, Discovery and Development P01 Special Emphasis Review Panel, NCI, SRA: Dr. Peter Wirth, Washington, DC

2006 Chair, IMPaCT (Innovative Minds in Prostate Cancer Today) Abstract Committee Meeting, SAIC (Science Applications International Corp.), Congressionally Directed Medical Research Programs, April 2006, Washington, DC

2006 Reviewer, Irish Clinical Research Grants

2007 Chair, Cell Biology Review Panel, Department of Defense Breast Cancer Research Program

2007 Reviewer, American Urological Association Research Foundation
Scholarship Awards
2007-2008 Reviewer, National Medical Research Council, Ministry of Health,
Singapore
2008 External Reviewer, Michael Smith Foundation, Vancouver, British Columbia.
2008 Reviewer, Science Foundation Ireland, Dublin, Ireland
2008 Acting Chair, George O'Brien Urology Research Centers (P50 Program)
Reviews, NIH/NIDDK
2008 Reviewer, Prostate Cancer Foundation of Australia, Melbourne, Australia
2008 Reviewer, Academy of Sciences of the Czech Republic, Prague, Czech
Republic

Consulting Activities:

1997 – 2003 Consultant, Pfizer Pharmaceuticals (Doxazosin Clinical Program)

Officer:

2003 – 2005 President, Society for Basic Urologic Research (SBUR)

Conference Organizer:

1999 – 2000 Organizing Committee, SBUR 2000 Fall Symposium on Prostate Cancer
2000 – 2001 Conference Chair, SBUR Fall 2001 Meeting/World Congress in Urologic
Research, Tucson, Arizona
2001 – 2002 Member, Advisory Board, 2002 International Symposium in Prostate
Cancer, Baltimore MD
2001 – 2002 Member, Organizing Committee, SBUR Fall 2002 Symposium, Tucson,
AZ
2002 – 2003 Member, Organizing Committee, Fifth World Congress in Urologic
Research, London, UK
2003 – 2004 Member, Organizing Committee, SBUR Fall 2004 Meeting, Savannah,
GA
2004 Organizer, SBUR Satellite Symposium, ESUR 2004 Congress, Athens,
Greece
2004 – 2005 Member, Program Organizing Committee, AUA 2005 Meeting, San
Antonio, TX
2005 Member, Organizing Committee, NPG Symposium in Uro pharmacology/
SBUR Fall 2005 Meeting, Miami Beach, FL
2005-2006 Member, Program Organizing Committee, AUA 2006 Meeting, Atlanta,
GA
2005-2006 Member, Organizing Committee, SBUR Spring 2006 Meeting, Atlanta, GA
2006-2007 Chair, IMPaCT (Innovative Minds in Prostate Cancer Today) Organizing
Committee, Abstract Committee, SAIC (Science Applications
International Corp.), Congressionally Directed Medical Research
Programs

Board Memberships:

1999 – 2001 Member, Executive Board, Society for Basic Urologic Research
2001- Board Member, International Prostate Health Council
2004 - Member, American Urological Association Education Council

XI. Editorial Boards:

2000–Present Associate Editor, *The Prostate*
2005–Present Associate Editor, *Cancer Research*
2006-2009 Associate Editor, *British Journal of Pharmacology*
2007–Present Associate Editor, *AUA News*
2008–Present Editorial Board, *The Open Prostate Cancer Journal*

XII. Editorial Consultant/Reviewer:

American Journal of Pathology
Apoptosis
Archives of Pharmacology
Biochimica Biophysica Acta
British Journal of Cancer
British Journal of Urology
British Journal of Urology International
Cancer
Cancer Research
Cancer Chemotherapy and Pharmacology
Cancer Detection and Prevention
Cancer Gene Therapy
Cancer Letters
Cell Death and Differentiation
Clinical Cancer Research
Endocrinology
Endocrine-Related Cancer
European Journal of Cancer Genetics
European Journal of Endocrinology
European Urology
Experimental Cell Research
FEBS Letters
Journal of Cellular Biochemistry
Journal of Histochemistry and Cytochemistry
Journal of National Cancer Institute
Journal of Steroid Biochemistry
Journal of Urology
International Journal of Andrology

International Journal of Cancer
Mini Reviews in Medicinal Chemistry
Molecular Cancer
Molecular Cancer Research
Molecular Cancer Therapeutics
Molecular Carcinogenesis
Proceedings of National Academy of Science (PNAS)
Neoplasia
Oncogene
Oncology Research
The Prostate
Prostate Cancer and Prostatic Diseases
Science
Systems Biology in Reproductive Medicine
Tissue and Cell Research
Urology

XIII. Research Support:

Active:

NIH/NCI R01 CA10757
Principal Investigator (**Kyprianou, Natasha**) 20% effort
“Induction of Prostate Anoikis by Quinazolines”
5/04-4/09 Direct Costs \$200,000/year

NIH RR-03-014
Centers for Biomedical Research Excellence (COBRE)
PI: Hersh, Louis 10% effort
Project 5: “Dissecting the Cell Surface Proteome of Prostate Cancer”
Project leader: Zhu, Haining
Co-Principal Investigator (5% effort): **Kyprianou, Natasha**
9/04-8/09 Direct Costs \$1,371,188/year

American Urological association Research Foundation Scholarship
Preceptor
Scholar: Shinichi Sakamoto, M.D., Ph.D.
Mentor/Preceptor: **Natasha Kyprianou**
“Role of Talin in Human Prostate Cancer Progression and Metastasis”
7/08-6/09

Department of Defense/Congressionally Directed Prostate Cancer Programs/PCRP
Synergistic Development Award: PI: Kyprianou, Natasha/Partnering PI: Zhu, Haining
Department of Defense, PCRP, PC074317 Synergistic Grant, Co-Investigator: **Kyprianou, Natasha (10% effort)**; Partnering Co-Investigator, Haining Zhu; Project Title: “Biomarker Discovery and Mechanistic Studies of Prostate Cancer Using Targeted Proteomic Approaches”
2008-2011

NIH 2 P42 ES 007380
Superfund Basic Research Program
PI: Toborek, Michal 5% effort
Co-Investigator **Kyprianou, Natasha**
“Vascular Mechanisms of PCB-Induced Brain Metastases” (Project #3)
4/05-3/10 Direct Costs \$2,595,400

UK Markey Foundation Cancer Research Award:
Principal Investigator: **Kyprianou, Natasha**
Project Title: EMMPRIN as a new molecular marker of prostate cancer progression.
Total Costs: \$ 75,000 02/08-01/09

NIH R01 R01 AT 2890-01A2
PI: Damodaran Chendil 20% effort; Co-Investigator: **Kyprianou, Natasha-5% effort**
“A Novel Herbal Medicine for the Treatment of Prostate Cancer”
2006-2010 Direct Costs \$250,000/year

Pending:

American Cancer Society
Principal Investigator: Damodaran Chendil
Co-Investigator: **Kyprianou, Natasha** 5% effort
“The Effect of Dietary Molecule, Withaferin-A on Prostate Cancer”
7/1/09-6/30/13 Direct Costs: \$240,000/year

NIH/NIDDK R01 GRANT00491815
Principal Investigator: **Kyprianou, Natasha** 25% effort
“Novel Effects of TGF- β Signaling in Prostate Growth Regulation and Tumor Progression”
4/1/09-3/31/14 Direct Costs: \$250,000/year

NIH R01 Proposal
PI: Haining Zhu 25% effort
Co-Investigator: **Kyprianou, Natasha-10% effort**
“Functional Analysis of the Cell Surface Proteins Associated with Metastatic Prostate Cancer”
07/2008-06/30/2013 Direct Costs: \$225,000/year

NIH, T-32 Training Grant
PI: William Balke Mentor: **Kyprianou, Natasha**
“University of Kentucky Predoctoral Clinical Research Training Program”
2007-2010

NIH

PI: Damodaran Chendil

Co-Investigator: **Kyprianou, Natasha** 5% effort

“Extrinsic apoptosis regulation by novel ubiquitin ligases”

07/2009-06/2014

Patents and Inventions:

Patent (Provisional) US Patent and Trademark Office (USTPTO)- University of Kentucky
Invention, “**Treatment of Prostate Cancer with Angiogenesis-targeting Quinazoline-based
Anti-cancer Compounds**”- November 2007

XIV. Research Fellows, Postdoctoral Fellows, Residents:

1992 – 1993	Geoffrey Sklar, M.D., Resident Current Position: Associate Professor and Chief, Division of Urology University of Maryland Medical Center, Baltimore
1992 – 1993	Tracy Burney, M.D., Resident Current Position: University of Florida, Orlando
1992 – 1995	Huacheng Tu, M.D., Postdoctoral Fellow
1992 – 1994	Neena Bains, M.D., Postdoctoral Fellow
1993	Shammai Rockove, M.D., Resident Current Position: Assistant Professor of Urology University of Oregon, Portland
1993 – 1994	Ronald Benoit, M.D., Resident Current Position: Assistant Professor of Urology University of Pittsburgh, Pittsburgh
1993 – 1994	Walter Sartor, M.D., Resident Current Position: General Surgery Resident
1994 – 1995	Edward King, M.D., Resident Current Position: Urology Attending, Florida
1994 – 1995	Derrick Burno, M.D., Resident Current Position: Private Practice Urologist, New Jersey
1995 – 1996	Steven Rock, M.D., Resident Current Position: Urology Attending/Private Practice, Maryland
1995 – 1996	Juan Montogia, M.D., Resident Current Position: Urology Attending, Texas
1996 – 1997	Jennifer Berman, M.D., Resident Current Position: Assistant Professor of Urology/UCLA, Los Angeles
1996 – 1997	Timothy Mackey, M.D., Resident Current Position: Urology Attending, New Jersey
1997 – 1998	David Sigman, M.D., Resident Current Position: Assistant Professor of Urology Sinai Medical Center, Baltimore

1997 – 1998 Joanna Chon, M.D., Resident
Current Position: Assistant Professor of Urology
Thomas Jefferson University, Philadelphia

1998 – 1999 Joseph Del Pizzo, M.D., Resident
Current Position: Assistant Professor of Urology/Director of
Endourology, Cornell Medical School, New York

1998 – 1999 Deborah Glassman, M.D., Resident
Current Position: Assistant Professor of Urology
Thomas Jefferson University, Philadelphia

1999 – 2000 Michael Szostak, M.D., Resident
Current Position: Urologist, West Palm Beach, Florida

1999 – 2001 Elizabeth Bruckheimer, Ph.D. (AFUD Scholar, 2000-2002),
Postdoctoral Fellow

1999 – 2001 Kaspar Keledjian, M.D., Postdoctoral Fellow

2000 – 2001 David Cuellar, M.D., Resident
Current Position: Urologist, Dallas, TX

2000 – 2002 Ian Anglin, Ph.D., Postdoctoral Fellow

2001 – 2002 Brian Hill, M.D., Resident
Current Position: Urologist, Atlanta, GA

2002 – 2003 Ash Vyas, M.D., Postdoctoral Fellow

2002 – 2003 Li Zeng, M.D., Ph.D., Visiting Scientist, Associate Professor of
Pathology; University of Beijing Urologic Institute

2003 – 2004 Anastasios Tahmatzopoulos, M.D., Postdoctoral Fellow

2004 – 2005 Shaun McKenzie, M.D., Resident
Current Position: General Surgery Resident University of Kentucky
Medical Center, Lexington, Kentucky

2004 – 2006 Gabriella Rennebeck, Ph.D., Postdoctoral Fellow

2004 – present Brian Zhu, M.D., Ph.D., Postdoctoral Fellow

2006 – present Shinichi Sakamoto, M.D., Ph.D., Postdoctoral Research Fellow

2006 – present Hong Pu, M.D., Staff Scientist

Graduate Students:

1994 – 1998 Yanping Guo, Graduate Student, Ph.D. Program, Department of
Biochemistry and Molecular Biology, University of Maryland School of
Medicine

1994 – 1995 Rebecca Caldwell, Master's Program

1995 – 1996 David Bradbury, Master's Program

1996 Debra Stucker, Graduate Student (Rotation)

1998 Jingsong Zhu, Graduate Student (Rotation)

1999 – 2003 Rachel Winter, Ph.D. Program, Department of Biochemistry and
Molecular Biology, University of Maryland School of Medicine

2003 – 2007 Jason Garrison, IBS Program, Ph.D. Candidate, Department of Molecular
and Cellular Biochemistry, University of Kentucky College of Medicine

2004 – 2005 Menglei Zhu, Graduate Student, Graduate Program in Toxicology (Rotation)

2005 Enerlyn Lozada, Graduate Program in Toxicology (Rotation)

2005	William Velez, IBS Graduate Program, University of Kentucky (Rotation)
2005	Kate Zavietsva, IBS Graduate Program (Rotation)
2006	Shi Ping, Graduate Program in Toxicology (Rotation)
2006	Andreea Popa, IBS Graduate Program (Rotation)
2006 – 2007	Brynn Rybak, IBS Graduate Program, Ph.D. Candidate, Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine
2007	Michael Opata, IBS Graduate Program (Rotation)
2006 – 2007	William Velez, IBS Graduate Program, M.Sc. Candidate, Department of Molecular and Cellular Biochemistry, University of Kentucky
2007 – present	Meng Lei Zhu, Toxicology Graduate Program, Ph.D. Candidate, Graduate Center for Toxicology, University of Kentucky College of Medicine
2007 – 2008	Gang Wang, Ph.D. Candidate, University of British Columbia, External Examiner
2008	Yuqian Zhang, Department of Molecular and Cellular Biochemistry, University of Kentucky, Seminar Advisor.
2008 – present	Joanne Collazo, Toxicology Graduate Program, Ph.D. Candidate, Graduate Center for Toxicology, University of Kentucky College of Medicine

Medical Students:

1994	James Matteson, University of Maryland School of Medicine
1995	Michael Franks, University of Maryland School of Medicine
1996 – 1997	Juan Litvak, University of Maryland School of Medicine
1998	Priti Kaur, University of Maryland School of Medicine
1998 – 1999	Andrew Kramer, University of Maryland School of Medicine
2000 – 2001	Grace Kim, University of Maryland School of Medicine (M.D./Ph.D. Program)
2003	Kuwong Mwamukonda, University of Kentucky College of Medicine
2003 – 2004	Aaron Becker, University of Kentucky College of Medicine
2004 – 2005	Jason Bylund, University of Kentucky College of Medicine
2005 – 2007	Andrew Harris, University of Kentucky College of Medicine
2005	Daniel S. Bramer, University of Kentucky College of Medicine
2005	John Williams, University of Kentucky College of Medicine
2005	Jeffrey Nix, University of Kentucky College of Medicine
2006	Jamie Messer, University of Kentucky College of Medicine
2006	Adam Vogt, University of Kentucky College of Medicine
2006	Justin Dixon, University of Kentucky College of Medicine
2007	Garret Korret, University of Kentucky College of Medicine
2007 – 2009	Ryan Reynolds, University of Virginia School of Medicine
2007	Justin Johnson, University of Kentucky College of Medicine
2007 – present	Dustin Gayheart, University of Kentucky College of Medicine
2008	John Paul Scopetta, University of Kentucky College of Medicine

Undergraduate Students:

2001	Kokab Bargandi, University of Maryland, Baltimore, MD
2002	Melissa Yingling, University of Virginia, Charlottesville, VA
2003	M. Tandy Suttton, Transylvania University, Lexington, KY
2004	Joel Carter, University of Kentucky, Lexington, KY
2004	Matthew Martelli, University of South, Sewanee
2005	Ryan Reynolds, Center College, KY
2005	Jackie Ryan, Davidson College, S.C.
2006 – 2008	Eric Lin, Stanford University, CA
2008	Elisabeth Jones, University of Kentucky, Lexington, KY
2009	Hesham Shehata, Transylvania University

Faculty Mentoring:

1997 – 2000	Toby Chai, M.D., Associate Professor of Urology/Surgery, University of Maryland Medical Center, Baltimore
2003 – 2006	Haining Zhu, Ph.D., Assistant Professor of Molecular and Cellular Biochemistry, University of Kentucky, Lexington
2005 – present	Damodaran Chendil, Ph.D., Assistant Professor of Clinical Laboratory Sciences, University of Kentucky, Lexington
2005 – present	Steven Schwarze, Ph.D., Assistant Professor of Molecular and Cellular Biochemistry, University of Kentucky, Lexington
2006 – 2008	Vernon Pais, M.D., Assistant Professor of Urology, Department of Surgery, University of Kentucky, Lexington
2006 – 2008	Kyung-Bo Kim, Ph.D., Assistant Professor of Pharmaceutical Sciences, University of Kentucky, Lexington
2007 – present	Andrew Bernard, M.D., Assistant Professor of Surgery, Department of Surgery, University of Kentucky Medical Center

XV. Visiting Professorships:

June 1992	Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York
June 1995	Department of Urology and the Cancer Center, University of Chicago School of Medicine, Chicago
Oct. 1996	Department of Urology, Northwestern University, Chicago, Illinois
Feb. 1997	Department of Urology, Cornell Medical Center-New York Hospital, NY
June 1997	Brady Urologic Research Institute, Department of Urology and the Oncology Center, Johns Hopkins School of Medicine
July 1998	Department of Urology, University of Tennessee, Knoxville, TN
Nov. 1999	General Post and Telecom. Hospital, Beijing, PRC
Feb. 2000	Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA
May 2000	Urology Grand Rounds, Sinai Hospital, Baltimore, MD

Oct. 2000 Department of Urology and the Prostate Cancer Program, University of Iowa, Iowa City, Iowa

April 2001 Department of Urology and Institute of Aging, University of Innsbruck, Innsbruck, Austria

May 2001 Pfizer Pharmaceuticals, Sandwich, UK

Sept. 2001 Department of Cell Biology, Georgetown University, Washington D.C.

Sept. 2002 Department of Anatomy, University of Turku, Turku, Finland

March 2003 Department of Cell Biology and Anatomy, Medical College of Georgia, Augusta

May 2003 Department of Medicinal Chemistry and Pharmacology, College of Pharmacy, Ohio State University, Columbus, OH

Oct. 2003 University of Massachusetts Medical School, Endocrinology Distinguished Lecture Series, Departments of Urology and Cell Biology, Worcester, MA

Nov. 2003 Department of Biological Sciences, University of Delaware

April 2004 Northwestern University Lurie Comprehensive Cancer Center, Chicago, IL

Sept. 2004 University of Nebraska Cancer Center, Omaha, Nebraska

March 2005 Department of Urology/Urologic Diseases Research Center, Children's Hospital/Harvard Medical School, Boston, MA.

April 2005 Department of Urology/Cell Biology and Cancer Center, University of Minneapolis, MN

April 2005 Department of Urology, Innsbruck University/Teaching Hospital of Feldkirch, Feldkirch, Austria

April 2005 Department of Pharmacology, University College, London, England

May 2005 The Lankenau Institute for Medical Research/Thomas Jefferson University, Philadelphia, PA

Sept. 2005 Department of Pharmaceutical Sciences, University of Louisiana School of Pharmacy, Monroe, LA

Sept. 2005 Comprehensive Cancer Center, Wake Forest University, Prostate Cancer Center of Excellence Retreat, Winston-Salem, NC

Oct. 2005 Departments of Urology and Pathology, University of Rochester, Rochester, NY

Nov. 2005 Department of Urology and the Winship Cancer Center, Elin Lecture Series, Emory University School of Medicine, Atlanta, GA

March 2006 Department of Oncological Sciences and the Cancer Center, Mount Sinai Medical School, New York, NY

March 2006 Department Cell Biology and Physiology, University of Miami Medical School, Miami, FL

May 2006 Department of Cell and Molecular Biology, University of Cincinnati, Cincinnati, OH

July 2006 Department of Hematology/Oncology, Cornell Medical School, New York, NY

Oct. 2006 Department of GI Oncology, M.D. Anderson Cancer Center, Houston, TX

February 2007 The Prostate Centre and Department of Urology, Vancouver General Hospital, Vancouver, Canada

March 2007 The Bernadin Cancer Center, Loyola Medical Center, Chicago, IL

May 2007	Department of Urologic Oncology, Roswell Park Cancer Institute, Buffalo, NY
November 2007	University of Pittsburgh Medical Center, Pittsburgh, PA
December 2007	Department of Urology, UT Southwestern Medical Center, Dallas, TX
February 2008	Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan
March 2008	Medical University of Innsbruck, Innsbruck, Austria
April 2008	Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA
October 2008	University of Louisville, Louisville, KY
October 2008	University of Texas M.D. Anderson Cancer Center, Department of Cancer Biology, Houston, TX

XVI. Invited Lectureships at National and International Meetings:

March 1992	Annual Meeting of the Radiation Research Society, Salt Lake City
March 1993	Symposium on “Apoptosis”. Joint Meeting of the German and Dutch Societies for Cell Biology, Munster, Germany
June 1994	Workshop on “Apoptosis in Hormone Dependent Cancers”, Berlin
July 1994	Gordon Conference in Reproductive Tract Biology. “Apoptosis in Development of Prostatic Tumors”; Plymouth State University, New Hampshire
August 1994	AUA Office of Education: Special Research Conference on Growth Factors in Urological Malignancies; Houston
October 1994	Tenth International Symposium on Cellular Endocrinology. “Molecular and Cell Biology of Apoptosis in Development, Disease and Cancer”; Lake Placid, New York
March 1995	Georgetown University Medical Center, Washington, D.C.
March 1995	86 th Annual Meeting, American Association for Cancer Research. Session on Translational Aspects of Prostatic Cancer”; Toronto
October 1995	37th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Panel on “Late Stage, Clinically Localized Prostate Cancer”; Miami Beach, Florida
November 1995	Selected Topics in Molecular Medicine: Lecture on Apoptosis, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania

December 1995 Fifth Annual Fall Meeting of the Society for Basic Urologic Research, Chapel Hill, North Carolina

January 1996 Selected Topics in Molecular Biology; Lecture on Apoptosis: Incidence, Significance and Detection. Bryn Mawr College, Pennsylvania

February 1996 NIH Course; Cellular and Molecular Approaches to the Study of Cancer and Genetic Diseases, NIH, Bethesda, Maryland

November 1996 Donald Coffey Urology Research Conference, West Palm Beach, Florida

December 1996 Sixth Annual Fall Symposium of the Society for Basic Urologic Research, Asilomar State Beach, California

January 1997 NIH Course; Molecular Approaches to the Study of Cancer and Genetic Diseases: Apoptosis in Prostate Cancer, Bethesda, Maryland

March 1997 Doxazosin Investigators Educational Exchange (DICE) Meeting; Effect of Doxazosin on Prostate Proliferation/Apoptosis; San Antonio

May 1997 Seminar Speaker, American Health Foundation, Valhalla, New York

September 1997 CapCURE Fourth Scientific Retreat, Lake Tahoe, Nevada

September 1997 Cardura Study Meeting, Washington D.C.

September 1997 American Hypertension Association; Adrenoceptors in Prostate Proliferation and Apoptosis, Washington, D.C.

March 1998 Lecture Series on Molecular Approaches to the Study of Cancer; On Apoptosis in Cancer Development and Treatment, NIH, Bethesda, Maryland

March 1998 International Symposium on Biology of Prostate Growth, Bethesda, NIH

March 1998 XIII Congress of the European Association of Urology, Barcelona

March 1998 89th Annual Meeting of the American Association for Cancer Research, "Molecular Markers for Cancer Detection", New Orleans

April 1998 International Doxazosin Exchange Meeting: Targeting Doxazosin for Prostate Cancer Therapy, Santa Fe, New Mexico

January 1999 Symposium on Diseases of the Prostate, West Palm Beach, Florida

March 1999 Apoptosis Lecture in Molecular Approaches to the Study of Cancer, NIH

May 1999	Annual Meeting of American Urological Association/SBUR Symposium, Dallas, Texas
July 1999	Innovators in Urology Second International Conference, Oxford, UK
August 1999	Gordon Conference in Hormonal Carcinogenesis, Tilton, New Hampshire
October 1999	Prouts Neck Meeting on Prostate Cancer, NCI, Prouts Neck, Maine
November 1999	Apoptosis in BPH and Prostate Cancer; Chinese Institute of Urology, Medical University of Beijing; Beijing, PRC
January 2000	International Symposium on BPH; Prostate Apoptosis, Tokyo
February 2000	International Cardura Symposium, Canary Islands, Spain
February 2000	Eighth European Urological Winter Forum, Davos, Switzerland
February 2000	International Prostate Health Council, Antwerp, Belgium
February 2000	International Apoptosis Advisory Panel Meeting, Sintra, Portugal
April 2000	XVth Congress of the European Urological Association, Apoptosis Symposium, Brussels, Belgium
June 2000	British Association of Urologic Surgeons (BAUS) Meeting, Birmingham, UK
September 2000	Innovators in Urology Third International Meeting, Dublin, Ireland
September 2000	15 th Hellenic Urological Congress, Corfu, Greece
February 2001	International CARDURA Meeting, Puerto Rico
April 2001	International BPH Consultation Meeting, Verona, Italy
May 2001	Urology Grand Rounds, Sinai Hospital, Baltimore, MD
March 2002	International Symposium on Diseases of the Prostate, Seville, Spain
April 2002	International Meeting on Male Ageing, Naples, Italy
June 2002	Prostate Cancer Forum, Oxford, England
September 2002	International Society of Urology, Stockholm, Sweden
September 2002	Molecular Mechanisms as Targets of Prostatic Disease, Liverpool, UK

September 2002	International Symposium on Prostate Cancer: New Perspectives, Baltimore, MD
November 2002	Ninth Prouts Neck Meeting on Prostate Cancer, Prouts Neck, Maine
February 2003	International Cardura Conference, St. Helena, Nappa Valley, CA
July 2003	Gordon Research Conference on Hormonal Carcinogenesis, Meriden, NH
September 2003	Fifth World Congress in Urologic Research, London, UK
February 2004	Cardura International Consultation Conference, Zurich, Switzerland
November 2004	European Society of Urologic Research (ESUR) 2004 Congress, Athens, Greece
December 2004	14 th Annual Meeting of the Society for Basic Urologic Research Fall 2004, Savannah, GA
April 2005	Prostate Cancer Symposium/Impact of prostate Cancer within the African-American Community, Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA
May 2005	Society for Urodynamics and Female Urology, Annual Meeting, San Antonio, TX
May 2005	Plenary Session Research Presentation American Urological Association Annual Meeting, San Antonio, TX
June 2005	8 th International Congress of Andrology, Seoul, Korea
December 2005	Nature/British Society of Pharmacology/SBUR Joint Symposium on Pharmacology of Urologic Diseases, Miami, FL
April 2007	American Society of Andrology Annual Meeting, Tampa, FL
September 2007	Chair, Apoptosis Symposium, IMPaCT Meeting/Department of Defense Research Programs, Atlanta, GA
September 2007	Plenary Session "Understanding the Role of Inflammation in Prostate Disease," 7th Urologic Research Congress, Dublin, Ireland
February 2008	17 th Annual Meeting of Japanese Society for Molecular and Cellular Urology, Tokyo, Japan

April 2008 Co-Chair, AACR Annual Meeting Minisymposium, “Molecular Pathways for Sex Hormone Signaling in Breast and Prostate Cancer”, San Diego, CA

November 2008 18th Annual Meeting of the Society for Basic Urologic Research, Symposium on Novel Therapies for Prostate Cancer, Phoenix, AZ

XVII. Book Reviews:

Denis, L.J., Behre, H.E., Griffiths, K., Krieg, M., **Kyprianou, N.**, Lee, C., Mahler, C.H., Pertisch, P., Prezioso, D., Prins, G.S., Tunn, U. and Vermeleun, A. Oestrogens and Prostatic Disease. Proceedings of an IHPC Group; *The Prostate*, 2000.

Kyprianou, N. and Jacobs, S.C. Apoptosis Induced by Alpha Blockers in the Prostate: A Novel Effect of “Old Drugs”, (Review) in *Current Urology Reports* (eds., J. Fitzpatrick and S.Kaplan). Vol. 1 (2):89-96, 2000.

Kyprianou, N. The induction of prostate apoptosis by alpha blockers. Web Teaching Course; Italian Program; 2003.

XVIII. Manuscripts, Peer-Reviewed:

1. **Kyprianou, N.**, Williams, H., Peeling, W., Davies, P. and Griffiths, K. Evaluation of biopsy techniques for androgen receptor assay in human prostatic tissue. *Br. J. Urol.*, 58:41-44, 1986.
2. **Kyprianou, N.**, and Davies, P. Association states of androgen receptors in nuclei of human benign hypertrophic prostate. *The Prostate*, 8:363-380, 1986.
3. **Kyprianou, N.**, Gingell, C. and Davies, P. Intranuclear distribution of androgen receptors in human prostate carcinoma. *J. Endocrinol.*, 112:161-169, 1987.
4. **Kyprianou, N.**, and Isaacs, J.T. The biological significance of measurable androgen levels in the rat ventral prostate following castration. *The Prostate*, 10:313-324, 1987.
5. **Kyprianou, N.** and Isaacs, J.T. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold concept. *The Prostate*, 11:41-50, 1987.
6. Isaacs, J.T. and **Kyprianou, N.** Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. *Urological Research*, 15:133-138, 1987.
7. Dunk, A.A., **Kyprianou, N.**, Davies, P., and Thomas, H.C. Human hepatocellular carcinoma tumor xenografts. *Digestive Diseases and Sciences*, 33(4):472-476, 1988.

8. **Kyprianou, N.** and Isaacs, J.T. Activation of programmed cell death in the rat ventral prostate following castration. *Endocrinology*, 122:552-562, 1988.
9. **Kyprianou, N.** and Isaacs, J.T. Identification of a cellular receptor for transforming growth factor-beta in the rat ventral prostate and its negative regulation by androgens. *Endocrinology*, 123:2124-2131, 1988.
10. **Kyprianou, N.,** English, H.F. and Isaacs, J.T. Activation of a Ca²⁺ Mg²⁺-dependent endonuclease as an early event in castration-induced prostatic cell death. *The Prostate*, 3:103-117, 1988.
11. **Kyprianou, N.** and Isaacs, J.T. Expression of transforming growth factor-β in rat ventral prostate during castration-induced programmed cell death. *Mol. Endocrinol.*, 3:1515-1522, 1989.
12. **Kyprianou, N.** and Isaacs, J.T. “Thymineless” death in androgen-independent prostatic cancer cells. *Biochem. Biophys. Res. Commun.*, 165:73-81, 1989.
13. English, H.F., **Kyprianou, N.,** and Isaacs, J.T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. *The Prostate*, 15:233-250, 1989.
14. **Kyprianou, N.,** and Isaacs, J.T. Relationship between metastatic ability and ras oncogene expression in rat mammary cancer cells transfected with v-H-ras oncogene. *Cancer Res.*, 50:1449-1454, 1990.
15. **Kyprianou, N.,** English, H.F. and Isaacs, J.T. Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. *Cancer Res.*, 50:3748-3753, 1990.
16. Ichikawa, T., **Kyprianou, N.,** and Isaacs, J.T. Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection. *Cancer Res.*, 50:6349-6357, 1990.
17. Martikainen, P., **Kyprianou, N.,** and Isaacs, J.T. Effect of transforming growth factor-β on proliferation and death of rat prostatic cells. *Endocrinology*, 127:2963-2968, 1990.
18. Isaacs, W.B., Isaacs, J.T., **Kyprianou, N.,** Burgers, J.K., Alexander, R.B., Partin, A.W., Mohler, J.L., Marshall, F.F. and Coffey, D.S. New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy. *Eur. Urol.*, 18 (Suppl.2): 33-35, 1990.
19. **Kyprianou, N.,** English, H.F., Davidson, N.E. and Isaacs, J.T. Programmed cell death during regression of MCF-7 human mammary cancer following estrogen ablation. *Cancer Res.*, 51:162-166, 1991.

20. **Kyprianou, N.**, Alexander, R.B. and Isaacs, J.T. Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. *J. Natl. Cancer Inst.*, 83:346-350, 1991.
21. Martikainen, P., **Kyprianou, N.**, Tucker, R.W. and Isaacs, J.T. Programmed death of non-proliferating androgen-independent prostatic cancer cells. *Cancer Res.*, 51:4693-4700, 1991.
22. Bartek, J., Bartkova, J., **Kyprianou, N.**, Lalani, E-N., Staskova, Z., Shearer, M., Chang, S. and Taylor-Papadimitriou, J. Efficient immortalization of luminal epithelial cells from the human mammary gland by introduction of SV40 large T antigen using a recombinant retrovirus. *Proc. Natl. Acad. Sci. USA.*, 88:3520-3524, 1991.
23. **Kyprianou, N.** and Taylor-Papadimitriou, J. Isolation of azatyrosine -induced revertants from ras-transformed human mammary epithelial cells. *Oncogene*, 7:57-63, 1992.
24. Isaacs, J.T., Lundmo, P.I., Berges, R. Martikainen, P., **Kyprianou, N.**, and English, H.F. Androgen regulation of programmed death of normal and malignant prostatic cells. *Journal of Andrology*, 13: 457-464, 1992.
25. D'Souza, B., Berdichevsky, F., **Kyprianou, N.**, and Taylor-Papadimitriou, J. Collagen induced morphogenesis and expression of the alpha-2 integrin subunit is inhibited in c-erb-2 transfected human mammary epithelial cells. *Oncogene*, 8: 1797-1806, 1993.
26. Taylor-Papadimitriou, J. D'Souza, Burchell, J., **Kyprianou, N.** and Berdichevsky, F. The role of tumor-associated antigens in the biology and immunotherapy of breast cancer. *Ann. N.Y. Acad. Sci.*, 698:31-47, 1993.
27. Bova, G.S., Carter, B.S., Bussemakers, M.J.G., Emi, M., Fujiwara, Y., **Kyprianou, N.**, Jacobs, S.C., Robinson, J.C., Epstein, J.I., Walsh, P.C. and Isaacs, W.B. Homozygous deletion and frequent allelic loss of 8p22 loci in human prostate cancer. *Cancer Res.*, 53:3869-3873, 1993.
28. Sklar, G.N., Eddy, H.A., Jacobs, S.C. and **Kyprianou, N.** Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. *J. Urol.*, 150:1526-1532, 1993.
29. **Kyprianou, N.**, Bains, A. K. and Jacobs, S.C. Induction of apoptosis in androgen-independent human prostate cancer cells undergoing "thymineless" death. *The Prostate*, 25:66-75, 1994.
30. Burney, T.L., Rockove, S., Eiseman, J., Jacobs, S.C. and **Kyprianou, N.** Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. *The Prostate*, 25:176-188, 1994.

31. Tu, H., Jacobs, S.C., Mergner, W.J. and **Kyprianou, N.** Absence of human papilloma virus type 16 and 18 in primary and metastatic human prostate cancer as detected by PCR analysis. *Urology*, 44:726-731, 1994.
32. **Kyprianou, N.** Apoptosis: Therapeutic significance in the treatment of androgen-dependent and independent prostate cancer. *World J. Urology*, 12:299-303, 1994.
33. Benoit, R.M., Eiseman, J. Jacobs, S.C. and **Kyprianou, N.** Reversion of prostate tumorigenic growth by azatyrosine. *Urology*, 46: 370-377, 1995.
34. Sartor, W.M., **Kyprianou, N.**, Fabian, D. and Lefor, A.T. Enhanced expression of ICAM-1 in a murine fibrosarcoma cell line reduces tumor growth rate. *J. Surgical Res.*, 59:66-74, 1995.
35. Burno, D.K., **Kyprianou, N.**, Sartor, W.M., Fabian, D.F., Turner, J. Vu, T., Patel, A., Trimbah, C. and Lefor, A.T. Transfection of a murine fibrosarcoma with ICAM-1 enhances the response to adoptive immunotherapy. *Surgery*, 118:237-244, 1995.
36. King, E.D., Matteson, J., Jacobs, S.C. and **Kyprianou, N.** Incidence of apoptosis, cell proliferation, and bcl-2 expression in transitional cell carcinoma of the bladder: correlation with tumor progression. *J. Urol.*, 155:316-320, 1996.
37. **Kyprianou, N.**, Tu, H., and Jacobs, S.C. Apoptotic and proliferative activities in human benign prostatic hyperplasia (BPH). *Human Pathology*, 27:668-675, 1996.
38. Tu, H., Jacobs, S.C., Borkowski, A. and **Kyprianou, N.** Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF- β_1 and bcl-2 expression. *Int. Journal of Cancer*, 69: 357-363, 1996.
39. **Kyprianou, N.**, King, E.D., Bradbury, D., and Rhee, J. Bcl-2 overexpression delays radiation-induced apoptosis without affecting clonogenic survival in human prostate cancer cells. *Int. Journal of Cancer*, 70:341-348, 1997.
40. Guo.Y., Jacobs, S.C., and **Kyprianou, N.** Down-regulation of protein and mRNA expression for TGF- β_1 type I and type II receptor in human prostate cancer. *International Journal of Cancer*, 71: 573-579, 1997.
41. **Kyprianou, N.**, Bains, A.K., and Rhee, J. Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of human prostate cancer cells. *The Prostate*, 32: 266-271, 1997.
42. Guo, Y., Sklar, G.N., Borkowski, A., and **Kyprianou, N.** Loss of cyclin-dependent kinase inhibitor p27^{Kip1} protein expression in human prostate cancer correlates with tumor grade. *Clin. Cancer Res.*, 3: 2269-2274, 1997.

43. **Kyprianou, N.**, Allen, L.F. and Wyllie, M.G. Induction of prostate apoptosis by doxazosin: alpha-adrenoceptor-dependent and -independent actions. *Br. J. Pharmacol.*, 22:283P, 1997.
44. Guo, Y., and **Kyprianou, N.** Overexpression of transforming growth factor (TGF)- β 1 type II receptor, restores TGF- β 1-sensitivity and signaling in human prostate cancer cells, LNCaP. *Cell Growth and Differentiation*, 9: 185-193, 1998.
45. **Kyprianou, N.**, and Rock, S. Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression. *Anticancer Res.*, 18 (2): 897-906, 1998.
46. Berman, J., McCarthy, M. M., and **Kyprianou, N.** Effect of estrogen- withdrawal on nitric oxide synthase expression and apoptosis in the rat vagina. *Urology*, 51:650-656, 1998.
47. **Kyprianou, N.**, Litvak, J., Borkowski, A., Alexander, R.B., and Jacobs, S.C. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia (BPH). *J. Urology*, 159:1810-1815, 1998.
48. Eiseman, J., Rogers, F., Kaufmann, J., Sentz, D., Guo, Y., Klinger, M.F., Callery, P.S. and **Kyprianou, N.** Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in enhanced radiosensitivity of human prostate cancer. *Cancer Res.*, 58: 4864-4870, 1998.
49. Mackey, T., Borkowski, A., Amin, P., Jacobs, S.C. and **Kyprianou, N.** Bcl-2/ bax ratio as a predictive marker of therapeutic response to radiotherapy in prostate cancer patients. *Urology*, 52:1085-1090, 1998.
50. **Kyprianou, N.** Induction of prostate apoptosis in response to α 1-adrenoceptor antagonists: Therapeutic significance in benign prostatic hyperplasia and prostate cancer. *The Prostate Journal*, 1(2) 11-20, 1999.
51. Guo, Y., and **Kyprianou, N.** Restoration of TGF- β signaling pathway suppresses tumorigenicity of human prostate cancer cells via induction of caspase-1 mediated apoptosis. *Cancer Res.*, 59:1366-1371, 1999.
52. Chon, J.K., Isaacs, J.T., Borkowski, A, Partin, A.W., Jacobs, S.C., and **Kyprianou, N.** α 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. *Journal of Urology*, 61:2002-2008, 1999.
53. Del Pizzo, J.J., Borkowski, D., Jacobs, S.C. and **Kyprianou, N.** Loss of p27^{Kip1} and cyclin E expression correlates with tumor grade and poor survival in transitional cell carcinoma of the bladder. *Am. J. Pathol.*, 155: 1129-1136, 1999.

54. Guo, Y., Sigman, D., Borkowski, A., and **Kyprianou, N.** Racial differences in prostate cancer growth: Apoptosis and cell proliferation in African-American and Caucasian patients. *The Prostate*, 42 (2): 130-136, 2000.
55. **Kyprianou, N.** and Benning, C.M. Suppression of human prostate cancer cell growth by α 1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. *Cancer Res.*, 60:4550-4555, 2000.
56. **Kyprianou, N.**, Chon, J., and Benning, C.M. Effects of α 1-adrenoceptor antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications in prostatic disease. *The Prostate* (Suppl.), 9: 42-46, 2000.
57. Bruckheimer, E. M. and **Kyprianou, N.** Apoptosis in Prostate Carcinogenesis: A Growth Regulator and a Therapeutic Target: A Review. *Cell and Tissue Research Special Issue on Apoptosis*, 301:153-162, 2000, Springer-Verlag.
58. Szostak, M., and **Kyprianou, N.** Radiation-induced apoptosis: Predictive and therapeutic significance in radiotherapy of prostate cancer. *Oncology Reports*; 7 (4): 699-706, 2000.
59. **Kyprianou, N.**, Bruckheimer, E.M. and Guo, Y. Cell Proliferation and Apoptosis in Prostate Cancer: Significance in Disease Progression and Therapy. *Histology and Histopathology*, 15: 1211-1223, 2000.
60. Glassman, D., Chon, J., Borkowski A., Jacobs, S.C. and **Kyprianou, N.** Combined effect of terazosin and finasteride on prostate apoptosis, cell proliferation and transforming growth factor- β expression in benign prostatic hyperplasia. *The Prostate*, 47:45-51, 2001.
61. Winter, R.M., Kramer, A., Borkowski A. and Kyprianou, N. Loss of caspase-1 and caspase-3 expression in human prostate cancer. *Cancer Res.*, 61: 1227-1232, 2001.
62. Szostak, M., Kaur, P., Amin, P., Jacobs, S.C. and **Kyprianou, N.** Apoptosis and Bcl-2 expression in prostate cancer: Significance in clinical outcome after brachytherapy. *Journal of Urology*, 165:2126-2130, 2001.
63. Bruckheimer, E.B., and **Kyprianou, N.** Dihydrotestosterone enhances TGF- β -induced apoptosis in hormone-sensitive prostate cancer cells. *Endocrinology*, 142:2419-2426, 2001.
64. Keledjian, K., Kim, G., Borkowski, A., Isaacs, J.T., Jacobs, S.C. and **Kyprianou, N.** Suppression of human prostate tumor vascularity by α 1-adrenoceptor antagonist, terazosin. *The Prostate*, 48:71-78, 2001.
65. Gill, J.K., Wang, L., Bretner, M., Winter, R., **Kyprianou, N.** and Hosmane, R.S. Potent in vitro anticancer activities of ring-expanded ("fat") nucleosides containing the imidazole [4,5-E][1,3] diazepine ring system. *Nucleosides, Nucleotides and Nucleic Acids*, 20:1043-1045, 2001.

66. Anglin, I., Glassman, D.T. and **Kyprianou, N.** Induction of Prostate Apoptosis by α 1-Adrenoceptor Antagonists: Mechanistic Significance of a Quinazoline Component. *Prostate Cancer and Prostatic Diseases*. 5: 88-95, 2002.
67. Hill, B., and **Kyprianou, N.** Sequencing Hormonal Therapy and Radiotherapy in Prostate Cancer: A Molecular and Therapeutic Perspective. *Oncology Reports*, 9:1151-1156, 2002.
68. Benning, C.M. and **Kyprianou, N.** Quinazoline-derived α 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an adrenoceptor-independent action. *Cancer Res.*, 62:597-603, 2002.
69. Cuellar, D., Rhee, J. and **Kyprianou, N.** α 1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. *Anticancer Res.*, 22: 1673-1680, 2002.
70. Bruckheimer, E.M. and **Kyprianou, N.** Bcl-2 antagonizes the combined apoptotic effect of TGF- β and dihydrotestosterone in prostate cancer cells. 53: 133-142, *The Prostate*, 2002.
71. Keledjian, K. and **Kyprianou, N.** Anoikis-induction by quinoxaline-based α 1-adrenoceptor antagonists doxazosin and terazosin in prostate cancer cells: Antagonistic effect of bcl-2. *Journal of Urology*, 169: 1150-1156, 2003.
72. **Kyprianou, N.** Doxazosin and terazosin suppress prostatic growth by inducing apoptosis. *Journal of Urology*, 169:1520-1529, 2003.
73. Partin, J. V., Anglin, I.E. and **Kyprianou, N.** Quinazoline-based α 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF- β signaling and I κ B induction. *Brit. J. Cancer*, 88:1615-1621, 2003.
74. Zeng, L., Rowland, R., Lele, S. and **Kyprianou, N.** Apoptosis incidence and expression of p53, TGF- β RII receptor, p27^{Kip1} and Smad4 in benign, premalignant and malignant human prostate. *Human Pathol.*, 35 (3):290-297, 2004.
75. Hill, B. and **Kyprianou, N.** Effect of Permixon on prostate cancer cell growth: Lack of apoptotic action. *The Prostate*, 61 (1): 73-80, 2004.
76. Winter, R.N., Rhee, J. and **Kyprianou, N.** Caspase-1 enhances the apoptotic sensitivity of human prostate cancer cells to ionizing irradiation. *Anticancer Research*, 24: 1377-1386, 2004.
77. Tahmatzopoulos, A. and **Kyprianou, N.** Apoptotic impact of α 1-adrenoceptor antagonists on prostate cancer growth: A myth or an inviting reality. *The Prostate*, 59:91-100, 2004.

78. Shaw, Y-J., Yang, Y-T., Garrison, J.B., **Kyprianou, N.** and Chen, C-S. Pharmacological exploitation of the alpha1 adrenoceptor antagonist doxazosin to develop a novel class of apoptosis-targeting antitumor agents that block intracellular protein kinase B/Akt activation. *J. Med. Chem.*, 47: 4453-4462, 2004.
79. Zeng, L. and **Kyprianou, N.** Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): Value in prostate cancer detection and prevention. *Prostate Cancer and Prostatic Diseases*, 8:7-13, 2005.
80. Keledjian, K., Garrison, B. J. and **Kyprianou, N.** Doxazosin inhibits vascular endothelial cell adhesion, migration and invasion. *J. Cell. Biochem.*, 94:374-388, 2005.
81. Tahmatzopoulos, A., LaGrange, A.C., Zeng, L., Mitchell, B., Conner, W. and **Kyprianou, N.** Effect of terazosin treatment on apoptosis and vascularity of bladder cancer patients. *UROLOGY*, 65:1019-1023, 2005.
82. Tahmatzopoulos, A., Sheng, S. and **Kyprianou, N.** Maspin sensitizes prostate cancer to doxazosin-induced apoptosis. *Oncogene*, 24:5375-5383, 2005.
83. Lee, Y.W., Nath, A., **Kyprianou, N.**, and Toborek, M. Human immunodeficiency virus-1 Tat protein upregulates IL-6 and IL-8 expression in human breast cancer cells. *Inflammation Res.*, 54: 380-389, 2005.
84. Rennebeck, G., Martelli, M. and **Kyprianou, N.** Anoikis and Survival Connections in the Tumor Microenvironment: Is there a Role in Prostate Cancer Metastasis. *Cancer Res.*, 65:11230-11235, 2005.
85. Garrison, J.B. and **Kyprianou, N.** Doxazosin induces anoikis of benign and malignant prostate epithelial cells via a death receptor mediated pathway. *Cancer Res.*, 66:464-472, 2006.
86. McKenzie, S. and **Kyprianou, N.** Apoptosis Evasion in Prostate Tumorigenesis: Significance in Therapeutic Resistance, *J. Cell. Biochem.*; 97:18-32, 2006.
87. Sutton, T.M., Yingling, M., Vyas, A., Atiemo, H., Borkowski, A., Jacobs, S.C. and **Kyprianou, N.** Finasteride targets prostate tissue vascularity by inhibiting cell adhesion and inducing apoptosis. *The Prostate*, 66:1194-1202, 2006.
88. Zhu, B., Fukada, K., Zhu, H. and **Kyprianou, N.** Prohibitin and Cofilin are intracellular effectors of TGF- β signaling in prostate cancer cells. *Cancer Research*, 66:8640-8647, 2006.
89. Garcia, G.E., Arevalo, N., Gupta, A., **Kyprianou, N.**, Kumar, A.P. Akt and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. *Neoplasia*, 8:523-533, 2006.
90. Isaacs, J., Pili, R., Qian, D., Dalrymple, S., Garrison, J., Kyprianou, N., Björk, A., Olsson, A., Leanderson, T. Identification of ABR-215050 as Lead Second Generation

Quinoline-3-Carboxamide Anti-Angiogenic Agent For the Treatment of Prostate Cancer. *The Prostate*, 66(16):1768-1778, 2006.

91. Harris, A.M., Warner, B.W, Wilson, J.M., Becker, A., Rowland, R.G., Conner, W., Lane, M., Kimbler, K., Durbin, E.B., Baron, A.T. and **Kyprianou, N.** Effect of α 1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort Study. *J. Urology*; 178:2176-2180, 2007.
92. Garrison, J.B., Shaw, Y-J., Chen, C-S. and **Kyprianou, N.** Novel Quinazoline-based Compounds Impair Prostate Tumorigenesis by Targeting Tumor Vascularity, *Cancer Research*, 67(23):11344-11352, 2007.
93. Zhu, M., Partin, J.V., Bruckheimer, E.M., Strup S.E. and **Kyprianou, N.** TGF- β signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. *The Prostate*, 68(3):287-295, 2008.
94. Sakamoto, S., Ryan, A.J. and **Kyprianou, N.** Targeting Vasculature in Urologic Tumors: Current Therapeutic Value, *J. Cell. Biochem*, 103(3):691-708, 2008.
95. Martin, F.M., Harris, A.M., Rowland, R.G., Conner, W., Lane, M., Durbin, E., Baron, A.T. and **Kyprianou, N.** Decreased Risk of Bladder Cancer in Men Treated with Quinazoline-Based α 1-Adrenoceptor Antagonists. *Gene Therapy & Molecular Biology*, 12(B):253-258, 2008.
96. Schwarze, S.R., Lin, E.W., Christian, P.A., Gayheart, D.T. and **Kyprianou, N.** Intracellular Death Platform Steps-In: Targeting Prostate Tumors via Endoplasmic Reticulum (ER) Apoptosis. *The Prostate*, 68:1615-1623, 2008.
97. McKenzie, S., Sakamoto, S., and **Kyprianou, N.** Maspin sensitizes apoptotic response of prostate cancer cells to hypoxia. *Oncogene*, 27:7171-7179, 2008.
98. Zhu, M.L., and **Kyprianou, N.** Androgen Receptor and Growth Factor Signaling Partnerships in Prostate Cancer Cells. *Endocrine Related Cancer*, 15:841-849, 2008.
99. Kumar, R., Srinivasan, S., Koduru, S., Pahari, P., Rohr, J., **Kyprianou, N.** and Damodaran, C. Psoralidin, an Herbal Molecule Inhibits PI3K Mediated Akt Signaling in Androgen Independent Prostate Cancer (AIPC) Cells. In Press, *Cancer Prevention*, 2008.
100. Zhu, B., Zhai, J., Zhu, H., and **Kyprianou, N.** Prohibitin Mediates Apoptotic Response to TGF- β Downstream of Raf-Erk and Inner Mitochondrial Membrane Permeability Changes. *Manuscript submitted to The EMBO Journal*, 2009.
101. Zhu, H., Zhao, J., Zhu, B, Huang, Z., Zhang, F., McCann, R.O., Toborek, M., Vien A, and **Kyprianou, N.** EMMPRIN overexpression on the cell surface proteome of prostate cancer cells correlates with metastatic phenotype, *Manuscript submitted for publication, Cancer Research*, 2009.

102. Sakamoto, S., McCann R.O. and **Kyprianou, N.** Talin as a novel regulator of prostate cancer progression and metastasis. *Manuscript submitted for publication, 2009.*
103. Pu, H., Colazzo, J., Vogt, A, Mitchell, B., and **Kyprianou, N.** Dysfunctional TGF- β signaling accelerates the onset of prostate tumorigenesis in the TRAMP Mouse model. *Manuscript submitted for publication, 2009.*

Invited Reviews:

1. Cuellar, D. and **Kyprianou, N.** Recent Advances in Medical Therapy of Benign Prostatic Hyperplasia (Review) in *Current Urology Reports* (Ed., B. Djovan). 11:27-33, 2001.
2. Garrison, J.B. and **Kyprianou, N.** “Novel Targeting of Anoikis for Prostate Cancer Therapy” *Current Cancer Drug Targets; (Apoptosis and Cancer Therapeutics)*, 4:85-95, 2004.
3. Tahmatzopoulos, A, Rowland, R.G. and **Kyprianou, N.** “The Role of Alpha Blockers in the Management of Prostate Cancer” in *Expert Opinion on Pharmacotherapy*; 5: 1279-1285, 2004.
4. Zhu, B. and **Kyprianou, N.** TGF- β Signaling in Prostate Cancer. *Cancer Treat. Res.*, 126:157-173, 2005.
5. Reynolds, R.A. and **Kyprianou, N.** Growth Factor Signaling in Prostatic Growth: Significance in Tumour Development and Therapeutic Targeting. *British Journal of Pharmacology*, 147:S144-S152, 2006.
6. Jones, E. and **Kyprianou, N.** Targeting TGF- β in Prostate Cancer: Therapeutic Opportunities. In Press, *Expert Opinion in Molecular Medicine*, 2009.

Manuscripts in Preparation:

1. Zhu, B., Zhu, H. and **Kyprianou, N.** Cofilin regulates prostate cancer cell invasion response to TGF- β . *Manuscript in preparation, 2009.*
2. Gayheart, D., Pu, H., Ryan, J., Rennebeck, G., Mitchell, B. and **Kyprianou, N.** PARP-knockout mice develop prostatic intraepithelial neoplasia and hyperplasia: Impact of aging on the phenotype. *Manuscript in preparation, 2009.*
3. Zhu, M. and **Kyprianou, N.** Androgens and transforming growth-factor- β Cross-talk to promote EMT in Prostate Cancer Cells. *Manuscript in preparation, 2009.*
4. Vyas, A., Garrison, J.B. and **Kyprianou, N.** Effect of quinazoline-based adrenoceptor antagonists, terazosin and doxazosin, but not the sulphonamide, tamsulosin, to induce prostate cell apoptosis in BPH. *Manuscript in preparation, 2009.*

5. Sakamoto, S. and **Kyprianou, N.** Targeting Renal Cancer growth via quinazoline-induced anoikis inhibits proliferation of benign and malignant prostate cells. *Manuscript in preparation*, 2009.

XIX. Books and Book Chapters:

1. Isaacs, J.T. and **Kyprianou, N.** Biological basis for combined chemohormonal therapy for prostatic cancer. In *New Trends in Diagnosis and Treatment of Prostatic Cancer*. Acta Medica Edizioni Congress, pp.241-255, 1987.
2. Isaacs, J.T., Schulze, H. and **Kyprianou, N.** Experimental studies on the optimal therapy for prostatic cancer. In *The Prostate* (Fitzpatrick and Krane, Eds.), Churchill Livingstone, London, pp. 33-40, 1989.
3. Isaacs, J.T. and **Kyprianou, N.** Biological basis for chemohormonal therapy for prostatic cancer. In *Urologic Oncology* (Lepor, H. and Ratliff, T.L., Eds.), Kluwer Academic Publishers, Boston, pp. 177-193, 1989.
4. **Kyprianou, N.**, Martikainen, P. and Isaacs J.T. Programmed cell death of normal and malignant prostatic cells. In *Endocrine Dependent Tumors* (Voigt, K-D. and Knabbe, C., Eds), Raven Press Ltd, New York, pp. 69-81, 1991.
5. **Kyprianou, N.**, Bartek, J. and Taylor-Papadimitriou, J. Effects of v-H-ras oncogene on immortalized non-tumorigenic human mammary epithelial cells. In *The Superfamily of Ras-related Genes* (Spandidos, D.A., ed.). NATO ASI Series, Plenum Press, New York, pp. 317-326, 1991.
6. **Kyprianou, N.**, Martikainen, P., Davis, L., English, H.F. and Isaacs, J.T. Programmed Cell Death as a New Target for Prostatic Cancer Therapy. *Cancer Surveys*, Vol. 11: Prostate Cancer, pp. 265-277, Imperial Cancer Research Fund, 1991.
7. **Kyprianou, N.** Therapeutic Significance of Apoptosis in the Treatment of Prostate Cancer. In: "Apoptosis in Hormone Dependent Cancers" *Schering Research Foundation Workshop*, (Eds) Michna, H. and Tenniswood M., Springer-Verlag, Berlin, New York, pp. 57-69, 1994.
8. **Kyprianou, N.** Role of Apoptosis in Development of Benign Prostatic Hyperplasia (BPH) and Prostatic Cancer: Clinical Significance in Diagnosis and Treatment. in *Prostate: Basic and Clinical Aspects*; Naz. R. (Ed.), CRC Press, pp. 181-199, 1997.
9. **Kyprianou, N.** Tissue proliferation and apoptosis: differential effects of alpha-adrenoceptor antagonists. In *Textbook of Benign Prostatic Hyperplasia* (eds. Kirby, R.S., McConnell, J.D., Fitzpatrick, J.M., Boyle, P., Wyllie, M.G.) (1st edition), Isis Medical Media Ltd., Oxford, Chapter 36, pp 13-18, 2000.

10. Bruckheimer, E.M. and **Kyprianou, N.** Apoptosis and Cell Cycle Deregulation in Prostate Cancer *in* Prostate Cancer: Scientific and Clinical Aspects-Bridging the Gap; (El-Lalani, N. and Abel, P.; eds), Imperial College Press, London, 2003, pp.511-549.
11. **Kyprianou, N.** The Differential Effects of Adrenoceptor Antagonists on Prostate Tissue Growth. In Textbook of Benign Prostatic Hyperplasia; Chapter 26; Eds. Kirby, R., McConnell, JD, Fitzpatrick, JM, Roehrborn, CG and Boyle, P. (2nd edition) Taylor and Francis Group, Abingdon, Oxon, UK. FL. pp 351-356, 2005.
12. Zhu, B. and **Kyprianou, N.** “TGF- β and Prostate Cancer” in *Cytokines and Cancer* (editor, Platanius, L); Kluwer Academic Publishers; 2005, pp. 157-173.
13. Bylund, J. Tahmatzopoulos, A. and **Kyprianou, N.** Growth Factor Signaling Pathways Regulating Prostate Growth in “Prostate Cancer: Principles and Practice” (Editors, Partin, A. Kirby, R., et al) 2006, Taylor and Francis, Oxford, pp 91-101.
14. Zhu, B. and **Kyprianou, N.** Transforming growth factor- β and cancer; in the “Molecular and Cellular Basis of Cancer”; The Cancer Textbook, (Editor, Alison, M.R.) 2007, Ch. 22, pp257-271.

Monographs and Editorials:

Kyprianou, N. Doxazosin research offers hope for combination BPH therapy. *Urology Times*, 25, (6), June issue, p.17, 1997.

Kyprianou, N. Spermine analogue doubles prostate cancer cells' radiation sensitivity by increasing apoptosis rate: New hope for prostate cancer therapy. *Urology Times*, 25 (11), December issue, p.25, 1997.

Kyprianou, N. and Mackey, T.M. High bcl-2/bax ratio points to greater risk of prostate cancer radiation failure. *Urology Times*, October issue, p.2, 1998.

Kyprianou, N. Induction of prostate apoptosis in response to Terazosin and Doxazosin in benign prostatic hyperplasia and prostate cancer. *Urology Times* supplement, Vol. 27 (2), June 1999.

Kyprianou, N. Activation of TGF- β signaling in human prostate cancer cells suppresses tumorigenicity via deregulation of cell cycle progression and induction of caspase-1 mediated apoptosis: Significance in prostate tumorigenesis. *Prostate Cancer and Prostatic Diseases*, Vol. 2 (Suppl. 3); November 1999.

Kyprianou, N. Induction of apoptosis by α 1-adrenoceptor antagonists in benign prostatic hyperplasia and prostate cancer. *Prostate Cancer and Prostatic Diseases*, Vol. 3 (Suppl. 1); S24-S25, December 2000.

Kyprianou, N. Apoptosis is the theme of the Society for Basic Urologic Research (SBUR) Spring 2004 meeting, *AUA News*, March/April 2004.

Kyprianou, N. Translational Research in Urology-Are We There Yet? *AUA News*, September 2007

Kyprianou, N. TGF- β signaling dictates therapeutic targeting in prostate cancer, *Therapy*, 5(1):7-11, 2008.

Kyprianou, N. Autophagy – Can Self-Cannibalism Find a Place in Urological Disease? *AUA News*, p. 12, May, 2008.

Kyprianou, N. Editorial Comment, “A duplex qPCR assay based on quantification of methylacyl-CoA racenase transcripts and prostate cancer antigen 3 in urine sediments for prostate cancer.” *J. Urol.*, June, 2009.

Last revised 1/14/09